Eliem Therapeutics, Inc. / Fundamentals

    Income statement

    Net revenue
    €0.00
    Cost of goods sold
    €0.00
    Gross profit
    €0.00
    SG&A expenses
    €20.45M
    R&D expenses
    €33.52M
    EBITDA
    -€54.53M
    D&A
    -€5.22M
    EBIT
    -€98.74M
    Interest expenses
    -€989.06K
    EBT
    -€44.81M
    Tax expenses
    €2.59M
    Net income
    -€44.81M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    -€1.87M
    Changes in working capital
    -€3.51M
    Operating cash flow
    -€39.86M
    Capex
    €66.34K
    Other investing cash flow
    €0.00
    Net investing cash flow
    -€234.08M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    -€7.72M
    Debt repayment
    €0.00
    Other financing cash flow
    €11.42M
    Net financing cash flow
    €3.70M
    Foreign exchange effects
    €421.30K
    Net change in cash
    -€239.01M
    Cash at end of period
    €19.54M
    Free cash flow
    -€39.79M

    Balance sheet

    Cash and cash equivalents
    €19.54M
    Cash and short-term investments
    €72.98M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €2.31M
    Total current assets
    €75.29M
    Property, plant & equipment
    €802.96K
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €89.66M
    Total non-current assets
    €90.46M
    Total assets
    €165.75M
    Accounts payable
    €815.03K
    Short-term debt
    €191.26K
    Other current liabilities
    €4.34M
    Total current liabilities
    €5.35M
    Long-term debt
    €359.27K
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €0.00
    Total non-current liabilities
    €359.27K
    Total liabilities
    €5.71M
    Common stock
    €6.03K
    Retained earnings
    -€223.42M
    Other equity
    €273.97K
    Total equity
    €160.04M
    Total liabilities and shareholders' equity
    €165.75M

    Company information

    Market capitalization
    €292.29M
    Employees
    9
    Enterprise Value
    -€1.55M

    Company ratios

    Gross margin
    0.0%
    EBITDA margin
    0.0%
    EBIT margin
    0.0%
    EBT margin
    0.0%
    Net margin
    0.0%
    ROE
    -28.0% Much better than peer group: -185.2%
    ROA
    -27.0% Much better than peer group: -291.7%
    Asset turnover
    0.0%
    FCF margin
    0.0%
    FCF yield
    -13.7%
    Efficiency ratio
    0.0%
    Net sales per employee
    €0.00
    Net income per employee
    -€4.98M

    Notifications